Microbial Therapy and Breast Cancer Management: Exploring Mechanisms, Clinical Efficacy, and Integration within the One Health Approach.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

One Health* ; Neoplasms*; Animals ; Humans ; Treatment Outcome ; Estrogens ; Cognition

This comprehensive review elucidates the profound relationship between the human microbiome and breast cancer management. Recent findings highlight the significance of microbial alterations in tissue, such as the gut and the breast, and their role in influencing the breast cancer risk, development, progression, and treatment outcomes. We delve into how the gut microbiome can modulate systemic inflammatory responses and estrogen levels, thereby impacting cancer initiation and therapeutic drug efficacy. Furthermore, we explore the unique microbial diversity within breast tissue, indicating potential imbalances brought about by cancer and highlighting specific microbes as promising therapeutic targets. Emphasizing a holistic One Health approach, this review underscores the importance of integrating insights from human, animal, and environmental health to gain a deeper understanding of the complex microbe-cancer interplay. As the field advances, the strategic manipulation of the microbiome and its metabolites presents innovative prospects for the enhancement of cancer diagnostics and therapeutics. However, rigorous clinical trials remain essential to confirm the potential of microbiota-based interventions in breast cancer management.

Sci Transl Med. 2014 Aug 13;6(249):249ra111. (PMID: 25122639)
Oncol Rep. 2013 Jun;29(6):2355-61. (PMID: 23525624)
Oncol Rep. 2013 Apr;29(4):1563-9. (PMID: 23338782)
PLoS One. 2013 Dec 18;8(12):e82659. (PMID: 24367534)
J Med Food. 2003 Winter;6(4):371-7. (PMID: 14977447)
J Immunother. 2015 Jun;38(5):185-96. (PMID: 25962107)
Vaccines (Basel). 2021 May 01;9(5):. (PMID: 34062708)
Cancer Lett. 2023 Feb 28;555:216041. (PMID: 36565918)
Front Oncol. 2022 Apr 28;12:891187. (PMID: 35574361)
World J Gastroenterol. 2013 Jan 14;19(2):185-98. (PMID: 23345941)
New Bioeth. 2017 Nov;23(3):210-218. (PMID: 29039256)
PLoS One. 2014 Jan 08;9(1):e83744. (PMID: 24421902)
Nat Rev Gastroenterol Hepatol. 2020 Oct;17(10):635-648. (PMID: 32647386)
Curr Top Microbiol Immunol. 2001;257:131-61. (PMID: 11417119)
Front Pharmacol. 2015 Nov 10;6:272. (PMID: 26617524)
Sci Rep. 2021 Jan 12;11(1):741. (PMID: 33436882)
Nutr Cancer. 2017 Feb-Mar;69(2):267-275. (PMID: 28094541)
Front Microbiol. 2022 Sep 23;13:899111. (PMID: 36212852)
Mol Ther Methods Clin Dev. 2022 Jul 31;26:532-546. (PMID: 36092362)
Biomed Pharmacother. 2021 Jun;138:111444. (PMID: 33662679)
Cancer Res. 2015 Apr 1;75(7):1197-204. (PMID: 25716681)
Int J Environ Res Public Health. 2020 Nov 30;17(23):. (PMID: 33265966)
Viruses. 2015 Mar 06;7(3):1020-61. (PMID: 25757062)
Front Immunol. 2022 Aug 12;13:983344. (PMID: 36032113)
Genome Med. 2021 Apr 16;13(1):60. (PMID: 33863341)
Nat Med. 2022 Apr;28(4):704-712. (PMID: 35228755)
Nat Commun. 2020 Jun 26;11(1):3259. (PMID: 32591509)
Biosci Biotechnol Biochem. 2007 Dec;71(12):2921-6. (PMID: 18159091)
J Clin Immunol. 2012 Dec;32(6):1353-9. (PMID: 22711009)
Lancet. 2020 Dec 5;396(10265):1817-1828. (PMID: 33278935)
Int J Mol Sci. 2023 Jul 24;24(14):. (PMID: 37511612)
Eur J Cancer. 2022 Jan;161:10-22. (PMID: 34896904)
Nat Ecol Evol. 2018 Jul;2(7):1065-1070. (PMID: 29784981)
Lancet. 1989 Jan 21;1(8630):164. (PMID: 2563083)
Recent Pat Inflamm Allergy Drug Discov. 2012 Jan;6(1):78-87. (PMID: 22185453)
Front Microbiol. 2021 Feb 25;12:584332. (PMID: 33716996)
Int J Nanomedicine. 2021 Dec 16;16:8159-8184. (PMID: 34938075)
Contemp Oncol (Pozn). 2012;16(4):285-9. (PMID: 23788896)
J Clin Oncol. 2016 Jul 20;34(21):2460-7. (PMID: 27138582)
Oncotarget. 2015 Apr 20;6(11):9387-96. (PMID: 25831236)
ACS Nano. 2021 Jul 27;15(7):11789-11805. (PMID: 34189924)
Bioengineered. 2015;6(4):187-92. (PMID: 25970137)
Oncotarget. 2021 Mar 16;12(6):521-524. (PMID: 33796220)
J Prim Care Community Health. 2023 Jan-Dec;14:21501319231186500. (PMID: 37449436)
BMC Complement Med Ther. 2023 Sep 26;23(1):339. (PMID: 37752516)
Adv Sci (Weinh). 2021 Mar 09;8(10):2003542. (PMID: 34026439)
Sci Rep. 2022 Nov 15;12(1):19547. (PMID: 36380060)
J Clin Oncol. 2012 Oct 10;30(29):3578-87. (PMID: 22927526)
Science. 2020 Oct 30;370(6516):. (PMID: 33122357)
Pathogens. 2023 Dec 19;13(1):. (PMID: 38276152)
Int J Mol Sci. 2023 Mar 05;24(5):. (PMID: 36902427)
Zoonoses Public Health. 2019 Feb;66(1):26-34. (PMID: 30390380)
N Engl J Med. 2022 Feb 10;386(6):556-567. (PMID: 35139274)
Cell. 2022 Apr 14;185(8):1356-1372.e26. (PMID: 35395179)
Nat Rev Drug Discov. 2016 Aug 30;15(9):660. (PMID: 30907381)
Cancer J. 2010 Jul-Aug;16(4):382-91. (PMID: 20693851)
Cancer Res. 2007 Apr 1;67(7):3201-9. (PMID: 17409428)
Microbiome. 2018 Aug 6;6(1):136. (PMID: 30081953)
Foods. 2019 Aug 01;8(8):. (PMID: 31374889)
Nat Rev Cancer. 2018 Oct;18(10):646-661. (PMID: 30116020)
Exp Mol Med. 2021 Oct;53(10):1636-1646. (PMID: 34707191)
NPJ Breast Cancer. 2022 Jul 29;8(1):89. (PMID: 35906259)
Science. 2015 Apr 3;348(6230):80-6. (PMID: 25838377)
Nat Commun. 2023 Mar 2;14(1):1191. (PMID: 36864029)
Appl Environ Microbiol. 2016 Jul 29;82(16):5039-48. (PMID: 27342554)
Front Microbiol. 2022 Dec 01;13:1030771. (PMID: 36532456)
Oncotarget. 2018 May 4;9(34):23396-23412. (PMID: 29805742)
Ann Oncol. 2019 Mar 1;30(3):397-404. (PMID: 30475950)
Cancer Cell Int. 2018 Feb 09;18:19. (PMID: 29449787)
Cytokine. 2017 Jan;89:160-172. (PMID: 26778055)
Cells. 2023 Jul 27;12(15):. (PMID: 37566024)
Exp Mol Med. 2019 Dec 11;51(12):1-15. (PMID: 31827064)
Breast Cancer Res Treat. 2018 Feb;167(3):671-686. (PMID: 29063313)
Cancer Res. 2021 Apr 15;81(8):2195-2206. (PMID: 33483370)
iScience. 2020 Jul 24;23(7):101269. (PMID: 32592998)
Ann Oncol. 2015 Jul;26(7):1446-51. (PMID: 25922060)
Front Oncol. 2020 Feb 12;10:120. (PMID: 32117767)
Ann Gastroenterol. 2016 Jan-Mar;29(1):56-62. (PMID: 26752951)
Cell. 2022 Sep 29;185(20):3807-3822.e12. (PMID: 36179671)
Microbiol Spectr. 2018 May;6(3):. (PMID: 29916349)
Toxins (Basel). 2016 Mar 16;8(3):. (PMID: 26999202)
Cell Host Microbe. 2014 Mar 12;15(3):306-16. (PMID: 24629337)
Curr Nutr Food Sci. 2013 Aug;9(3):194-200. (PMID: 23966890)
Environ Health Perspect. 2020 Dec;128(12):127008. (PMID: 33325755)
Science. 2020 May 29;368(6494):973-980. (PMID: 32467386)
Complement Ther Med. 2015 Jun;23(3):356-62. (PMID: 26051570)
Gut Microbes. 2023 Jan-Dec;15(1):2221452. (PMID: 37305949)
Cell Death Differ. 2021 Sep;28(9):2778-2796. (PMID: 33963313)
Radiat Oncol. 2010 May 05;5:31. (PMID: 20444243)
Cancer Res. 2021 Jul 15;81(14):3890-3904. (PMID: 34083249)
Breast Cancer. 2017 Mar;24(2):220-228. (PMID: 27709424)
BMJ Open Gastroenterol. 2017 Jul 3;4(1):e000145. (PMID: 28944067)
Front Oncol. 2022 Sep 07;12:953678. (PMID: 36158673)
J Cancer Res Clin Oncol. 2023 Mar;149(3):1285-1293. (PMID: 35441344)
Am J Chin Med. 2003;31(1):1-9. (PMID: 12723750)
Nat Med. 2023 Feb;29(2):450-457. (PMID: 36759673)
Front Bioeng Biotechnol. 2022 Oct 12;10:1026248. (PMID: 36312554)
Proc Biol Sci. 2019 Jan 16;286(1894):20182434. (PMID: 30963883)
Clin Cancer Res. 2021 Jun 1;27(11):3061-3068. (PMID: 33727258)
Nutr Rev. 2012 Aug;70 Suppl 1:S38-44. (PMID: 22861806)
Iowa Orthop J. 2006;26:154-8. (PMID: 16789469)
Signal Transduct Target Ther. 2023 May 25;8(1):217. (PMID: 37231000)
Cancers (Basel). 2020 Aug 31;12(9):. (PMID: 32878124)
Cancer Res. 2011 Apr 1;71(7):2466-75. (PMID: 21427357)
Microorganisms. 2022 Aug 27;10(9):. (PMID: 36144329)
Theranostics. 2021 May 3;11(14):6682-6702. (PMID: 34093847)
Sci Total Environ. 2021 Apr 1;763:142955. (PMID: 33109371)
Trends Microbiol. 2015 Feb;23(2):83-90. (PMID: 25455418)
J Biomed Sci. 2010 Mar 23;17(1):21. (PMID: 20331869)
Arzneimittelforschung. 2012 Nov;62(11):525-31. (PMID: 22945771)
J Clin Invest. 2020 Jan 2;130(1):466-479. (PMID: 31815742)
Nutrients. 2022 Feb 05;14(3):. (PMID: 35277029)
Evol Appl. 2021 Oct 08;14(11):2571-2575. (PMID: 34815739)
Nat Rev Cancer. 2017 May;17(5):271-285. (PMID: 28303904)
PLoS One. 2013 Jun 05;8(6):e65522. (PMID: 23755243)
Emerg Med Int. 2022 Aug 8;2022:8127137. (PMID: 35978704)
Eur J Public Health. 2018 Apr 1;28(2):327-332. (PMID: 29020283)
Toxics. 2023 Feb 16;11(2):. (PMID: 36851059)
Nat Commun. 2016 Aug 30;7:12684. (PMID: 27575253)
Sci Rep. 2017 Apr 19;7:46541. (PMID: 28422156)
J Immunol Res. 2021 Aug 26;2021:5061570. (PMID: 34485534)
Brain Behav Immun. 2020 Mar;85:186-191. (PMID: 30818031)
Semin Cancer Biol. 2022 Nov;86(Pt 3):666-681. (PMID: 34216789)
Cancers (Basel). 2022 Oct 09;14(19):. (PMID: 36230868)
Br J Cancer. 2007 Oct 22;97(8):1028-34. (PMID: 17895895)
Int J Mol Sci. 2021 Nov 30;22(23):. (PMID: 34884780)
Nat Rev Cancer. 2013 Nov;13(11):800-12. (PMID: 24132111)
Breast Cancer Res. 2023 Jul 10;25(1):82. (PMID: 37430354)
Lett Appl Microbiol. 2014 Jul;59(1):108-14. (PMID: 24635204)
Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):356-365. (PMID: 28270698)
Microorganisms. 2022 Jan 04;10(1):. (PMID: 35056547)
Front Cell Dev Biol. 2021 Nov 12;9:725821. (PMID: 34869313)
Biomaterials. 2022 Oct;289:121763. (PMID: 36055175)
Nat Rev Cancer. 2010 Nov;10(11):785-94. (PMID: 20944664)
Benef Microbes. 2019 Oct 14;10(7):751-758. (PMID: 31965846)
Nat Rev Microbiol. 2019 Jun;17(6):383-390. (PMID: 31089293)
Sci Total Environ. 2023 Mar 20;865:161264. (PMID: 36587700)
Int J Biol Macromol. 2017 Sep;102:565-570. (PMID: 28412340)
Oncol Rep. 2016 Mar;35(3):1741-9. (PMID: 26718317)
Oncoimmunology. 2017 Oct 16;7(2):e1382791. (PMID: 29308303)
Nat Med. 2018 Apr 10;24(4):392-400. (PMID: 29634682)
J Transl Med. 2012 Aug 17;10:167. (PMID: 22901246)
Cancer Cell. 2021 Sep 13;39(9):1202-1213.e6. (PMID: 34329585)
Front Public Health. 2014 Feb 13;2:14. (PMID: 24592380)
Appl Environ Microbiol. 2014 May;80(10):3007-14. (PMID: 24610844)
Int J Mol Sci. 2020 Sep 24;21(19):. (PMID: 32987946)
Cancer Cell. 2015 Jan 12;27(1):27-40. (PMID: 25533336)
Clin Nutr. 2014 Oct;33(5):761-7. (PMID: 24200199)

Keywords: breast cancer; microbial diversity; microbiome; microbiome immunomodulation; microbiota-based cancer therapies; one health

0 (Estrogens)

Date Created: 20240123 Date Completed: 20240124 Latest Revision: 20241023

20241023

PMC10816061

10.3390/ijms25021110

38256183